INBIOGEN Statistics
Total Valuation
INBIOGEN has a market cap or net worth of KRW 118.32 billion. The enterprise value is 115.01 billion.
Market Cap | 118.32B |
Enterprise Value | 115.01B |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
INBIOGEN has 9.98 million shares outstanding.
Current Share Class | 9.98M |
Shares Outstanding | 9.98M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.02% |
Owned by Institutions (%) | 0.00% |
Float | 2.06M |
Valuation Ratios
The trailing PE ratio is 12.37.
PE Ratio | 12.37 |
Forward PE | n/a |
PS Ratio | 16.18 |
PB Ratio | 0.73 |
P/TBV Ratio | 0.73 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.78, with an EV/FCF ratio of -64.81.
EV / Earnings | 12.03 |
EV / Sales | 15.73 |
EV / EBITDA | 11.78 |
EV / EBIT | 12.94 |
EV / FCF | -64.81 |
Financial Position
The company has a current ratio of 4.52, with a Debt / Equity ratio of 0.01.
Current Ratio | 4.52 |
Quick Ratio | 4.44 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | -0.47 |
Interest Coverage | -104.95 |
Financial Efficiency
Return on equity (ROE) is 6.00% and return on invested capital (ROIC) is -2.41%.
Return on Equity (ROE) | 6.00% |
Return on Assets (ROA) | -2.39% |
Return on Invested Capital (ROIC) | -2.41% |
Return on Capital Employed (ROCE) | -3.81% |
Revenue Per Employee | 178.33M |
Profits Per Employee | 233.22M |
Employee Count | 41 |
Asset Turnover | 0.05 |
Inventory Turnover | 13.86 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | 1.14 |
52-Week Price Change | n/a |
50-Day Moving Average | 9,857.80 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 51.48 |
Average Volume (20 Days) | 65,182 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, INBIOGEN had revenue of KRW 7.31 billion and earned 9.56 billion in profits.
Revenue | 7.31B |
Gross Profit | 265.60M |
Operating Income | -6.18B |
Pretax Income | 9.56B |
Net Income | 9.56B |
EBITDA | -5.31B |
EBIT | -6.18B |
Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 4.15 billion in cash and 839.93 million in debt, giving a net cash position of 3.31 billion or 331.33 per share.
Cash & Cash Equivalents | 4.15B |
Total Debt | 839.93M |
Net Cash | 3.31B |
Net Cash Per Share | 331.33 |
Equity (Book Value) | 161.62B |
Book Value Per Share | n/a |
Working Capital | 6.21B |
Cash Flow
In the last 12 months, operating cash flow was -1.68 billion and capital expenditures -99.14 million, giving a free cash flow of -1.77 billion.
Operating Cash Flow | -1.68B |
Capital Expenditures | -99.14M |
Free Cash Flow | -1.77B |
FCF Per Share | -177.73 |
Margins
Gross margin is 3.63%, with operating and profit margins of -84.53% and 130.78%.
Gross Margin | 3.63% |
Operating Margin | -84.53% |
Pretax Margin | 130.78% |
Profit Margin | 130.78% |
EBITDA Margin | -72.60% |
EBIT Margin | -84.53% |
FCF Margin | n/a |
Dividends & Yields
INBIOGEN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | 8.08% |
FCF Yield | -1.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on September 21, 2023. It was a reverse split with a ratio of 0.05.
Last Split Date | Sep 21, 2023 |
Split Type | Reverse |
Split Ratio | 0.05 |
Scores
INBIOGEN has an Altman Z-Score of 15.91.
Altman Z-Score | 15.91 |
Piotroski F-Score | n/a |